Duke Cancer Institute ( Site 0641)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Cutaneous Squamous Cell Carcinoma, Endometrial Cancer, Solid Tumor

Studies at this site

• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) — Completed